{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:40:14Z","timestamp":1709426414476},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Genitourinary malignancies have a substantial impact on men and women in the USA as they include three of the ten most common cancers (prostate, renal, and bladder). Other urinary tract cancers are less common (testis and penile) but still have profound treatment implications related to potential deficits in sexual, urinary, and reproductive function. Evidenced-based practice remains the cornerstone of treatment for urologic malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The authors reviewed the literature in consideration of the four top articles influencing clinical practice in the prior calendar year, 2022.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The PROTECT trial demonstrates favorable 15-years outcomes for active monitoring of localized prostate cancer. The SEMS trial establishes retroperitoneal lymph node dissection as a viable option for patients with seminoma of the testis with limited retroperitoneal lymph node metastases. CheckMate 274 supports adjuvant immunotherapy following radical cystectomy for muscle-invasive bladder cancer with a high risk of recurrence. Data reported from the IROCK consortium reinforce stereotactic ablative radiotherapy as an option for localized renal cell carcinoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The care for patients with urologic cancers has been greatly improved through advances in surgical, medical, and radiation oncologic treatments realized through prospective randomized clinical trials and large multicenter collaborative groups.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-023-14838-w","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:03:50Z","timestamp":1706803430000},"page":"2529-2537","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paradigm Shifting Research: Key Studies in Urologic Oncology"],"prefix":"10.1245","volume":"31","author":[{"given":"Shawn","family":"Dason","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"1","key":"14838_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"14838_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"issue":"24","key":"14838_CR3","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","volume":"379","author":"A Bill-Axelson","year":"2018","unstructured":"Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in prostate cancer: 29-Year Follow-up. N Engl J Med. 2018;379(24):2319\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1807801.","journal-title":"N Engl J Med"},{"issue":"9660","key":"14838_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","volume":"373","author":"A Widmark","year":"2009","unstructured":"Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(08)61815-2.","journal-title":"Lancet"},{"issue":"9809","key":"14838_CR5","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","volume":"378","author":"P Warde","year":"2011","unstructured":"Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(11)61095-7.","journal-title":"Lancet"},{"issue":"4","key":"14838_CR6","doi-asserted-by":"publisher","first-page":"EVID0a2300018","DOI":"10.1056\/EVIDoa2300018","volume":"2","author":"JL Donovan","year":"2023","unstructured":"Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid. 2023;2(4):EVID0a2300018. https:\/\/doi.org\/10.1056\/EVIDoa2300018.","journal-title":"NEJM Evid"},{"key":"14838_CR7","unstructured":"Guidelines Detail. NCCN. Accessed November 15, 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail"},{"issue":"3","key":"14838_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA\/ASTRO\/SUO Guideline: Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683\u201390. https:\/\/doi.org\/10.1016\/j.juro.2017.11.095.","journal-title":"J Urol"},{"issue":"3","key":"14838_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James ND, Clarke NW, Cook A, et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022;151(3):422\u201334. https:\/\/doi.org\/10.1002\/ijc.34018.","journal-title":"Int J Cancer"},{"issue":"16","key":"14838_CR10","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/JCO.22.00624","volume":"41","author":"S Daneshmand","year":"2023","unstructured":"Daneshmand S, Cary C, Masterson T, et al. Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. JCO. 2023;41(16):3009\u201318. https:\/\/doi.org\/10.1200\/JCO.22.00624.","journal-title":"JCO"},{"issue":"28","key":"14838_CR11","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2014.56.0896","volume":"32","author":"N Hanna","year":"2014","unstructured":"Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. JCO. 2014;32(28):3085\u201392. https:\/\/doi.org\/10.1200\/JCO.2014.56.0896.","journal-title":"JCO."},{"issue":"12","key":"14838_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.6004\/jnccn.2019.7369","volume":"17","author":"C Fung","year":"2019","unstructured":"Fung C, Dinh PC, Fossa SD, Travis LB. Testicular cancer survivorship. J Nat Compr Cancer Netw. 2019;17(12):1557\u201368. https:\/\/doi.org\/10.6004\/jnccn.2019.7369.","journal-title":"J Nat Compr Cancer Netw"},{"issue":"5","key":"14838_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409\u201336. https:\/\/doi.org\/10.3322\/caac.21731.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14838_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","volume":"84","author":"A Hiester","year":"2023","unstructured":"Hiester A, Che Y, Lusch A, et al. Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA\/B (PRIMETEST). Eur Urol. 2023;84(1):25\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2022.10.021.","journal-title":"Eur Urol."},{"key":"14838_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.06.004","author":"A Heidenreich","year":"2023","unstructured":"Heidenreich A, Paffenholz P, Hartmann F, Seelemeyer F, Pfister D. Retroperitoneal lymph node dissection in clinical stage IIA\/B metastatic seminoma: results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS). Eur Urol Oncol. 2023. https:\/\/doi.org\/10.1016\/j.euo.2023.06.004.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"14838_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.juro.2006.10.045","volume":"177","author":"SE Eggener","year":"2007","unstructured":"Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007;177(3):937\u201343. https:\/\/doi.org\/10.1016\/j.juro.2006.10.045.","journal-title":"J Urol"},{"issue":"5","key":"14838_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.eururo.2019.05.031","volume":"76","author":"AC Calaway","year":"2019","unstructured":"Calaway AC, Einhorn LH, Masterson TA, Foster RS, Cary C. Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer. Eur Urol. 2019;76(5):607\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2019.05.031.","journal-title":"Eur Urol"},{"issue":"22","key":"14838_CR18","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2034442.","journal-title":"N Engl J Med"},{"issue":"2","key":"14838_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"CL Vale","year":"2005","unstructured":"Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.006.","journal-title":"Eur Urol"},{"issue":"4","key":"14838_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/JU.0000000000001071","volume":"204","author":"N Almassi","year":"2020","unstructured":"Almassi N, Cha EK, Vertosick EA, et al. Trends in management and outcomes among patients with urothelial carcinoma undergoing radical cystectomy from 1995 to 2015: the Memorial Sloan Kettering experience. J Urol. 2020;204(4):677\u201384. https:\/\/doi.org\/10.1097\/JU.0000000000001071.","journal-title":"J Urol"},{"issue":"2","key":"14838_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","volume":"48","author":"CL Vale","year":"2005","unstructured":"Vale CL. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):189\u2013201. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.005.","journal-title":"Eur Urol"},{"issue":"11","key":"14838_CR22","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683.","journal-title":"N Engl J Med"},{"issue":"10232","key":"14838_CR23","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3.","journal-title":"Lancet"},{"issue":"12","key":"14838_CR24","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","volume":"23","author":"S Siva","year":"2022","unstructured":"Siva S, Ali M, Correa RJM, et al. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol. 2022;23(12):1508\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(22)00656-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"14838_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.036.","journal-title":"Eur Urol"},{"issue":"1","key":"14838_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.eururo.2011.03.030","volume":"60","author":"MAS Jewett","year":"2011","unstructured":"Jewett MAS, Mattar K, Basiuk J, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011;60(1):39\u201344. https:\/\/doi.org\/10.1016\/j.eururo.2011.03.030.","journal-title":"Eur Urol"},{"issue":"4","key":"14838_CR27","doi-asserted-by":"publisher","first-page":"166.e9","DOI":"10.1016\/j.urolonc.2021.12.018","volume":"40","author":"Y Freifeld","year":"2022","unstructured":"Freifeld Y, Pedrosa I, Mclaughlin M, et al. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urol Oncol Semin Orig Invest. 2022;40(4):166.e9-166.e13. https:\/\/doi.org\/10.1016\/j.urolonc.2021.12.018.","journal-title":"Urol Oncol Semin Orig Invest"},{"issue":"1","key":"14838_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/KCA-180044","volume":"3","author":"Y Freifeld","year":"2019","unstructured":"Freifeld Y, Margulis V, Woldu SL, Timmerman R, Brugarolas J, Hannan R. Stereotactic body radiation therapy for renal cell carcinoma with inferior vena cava thrombus: initial experience report and literature review. Kidney Cancer. 2019;3(1):71\u20137. https:\/\/doi.org\/10.3233\/KCA-180044.","journal-title":"Kidney Cancer"},{"issue":"2","key":"14838_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ucl.2023.01.007","volume":"50","author":"S Dason","year":"2023","unstructured":"Dason S, Mohebali J, Blute ML, Salari K. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Urol Clin North Am. 2023;50(2):261\u201384. https:\/\/doi.org\/10.1016\/j.ucl.2023.01.007.","journal-title":"Urol Clin North Am"},{"key":"14838_CR30","doi-asserted-by":"publisher","first-page":"e390038","DOI":"10.1200\/EDBK_390038","volume":"43","author":"S Dason","year":"2023","unstructured":"Dason S, Lacuna K, Hannan R, Singer EA, Runcie K. State of the art: multidisciplinary management of oligometastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2023;43:e390038. https:\/\/doi.org\/10.1200\/EDBK_390038.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"14838_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ucl.2023.01.013","volume":"50","author":"S Ray","year":"2023","unstructured":"Ray S, Dason S, Singer EA. Integrating surgery in the multidisciplinary care of advanced renal cell carcinoma. Urol Clin North Am. 2023;50(2):311\u201323. https:\/\/doi.org\/10.1016\/j.ucl.2023.01.013.","journal-title":"Urol Clin North Am"},{"issue":"5","key":"14838_CR32","doi-asserted-by":"publisher","first-page":"100692","DOI":"10.1016\/j.adro.2021.100692","volume":"6","author":"JE Schoenhals","year":"2021","unstructured":"Schoenhals JE, Mohamad O, Christie A, et al. Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma. Adv Radiat Oncol. 2021;6(5):100692. https:\/\/doi.org\/10.1016\/j.adro.2021.100692.","journal-title":"Adv Radiat Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14838-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14838-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14838-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:10:57Z","timestamp":1709424657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14838-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["14838"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14838-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SD is on the advisory boards of Bristol Myers Squibb and Roche and received educational funding from Intuitive Surgical), and CTL is a WebMD Bladder Cancer Podcast Host.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}